{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:53:24Z","timestamp":1764510804559,"version":"3.40.5"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R231\u2010A14057"],"award-info":[{"award-number":["R231\u2010A14057"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In clinical oncology, systemic 5\u2010fluorouracil (5\u2010FU) and its oral pro\u2010drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with standard doses of 5\u2010FU. <jats:italic>DPYD<\/jats:italic> genotyping and measurements of plasma uracil concentration (DPD phenotyping) can be applied as tests for DPD deficiency. In April 2020, the European Medicines Agency recommended pre\u2010treatment DPD testing to reduce the risk of 5\u2010FU\u2010related toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of this study is to present the current evidence for DPD testing in routine oncological practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two systematic literature searches were performed following the PRISMA guidelines. We identified studies examining the possible benefit of <jats:italic>DPYD<\/jats:italic> genotyping or DPD phenotyping on the toxicity risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Nine and 12 studies met the criteria for using <jats:italic>DPYD<\/jats:italic> genotyping and DPD phenotyping, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The evidence supporting either <jats:italic>DPYD<\/jats:italic> genotyping or DPD phenotyping as pre\u2010treatment tests to reduce 5\u2010FU toxicity is poor. Further evidence is still needed to fully understand and guide clinicians to dose by DPD activity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcpt.13782","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T12:54:09Z","timestamp":1661259249000},"page":"325-346","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["<i>DPYD<\/i> genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview"],"prefix":"10.1111","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-0645","authenticated-orcid":false,"given":"Niels Herluf","family":"Paulsen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Odense University Hospital  Odense Denmark"},{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fie","family":"Vojdeman","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry Holbaek Hospital  Holbaek Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig Ejdrup","family":"Andersen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit Zealand University Hospital  Roskilde Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-0721","authenticated-orcid":false,"given":"Troels K.","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Odense University Hospital  Odense Denmark"},{"name":"Department of Regional Health Research University of Southern Denmark  Esbjerg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Ewertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Plomgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Rigshospitalet, Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-7866","authenticated-orcid":false,"given":"Morten Rix","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Odense University Hospital  Odense Denmark"},{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"},{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-5515","authenticated-orcid":false,"given":"Peter Skov","family":"Esbech","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Odense University Hospital  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"},{"name":"Department of Oncology Odense University Hospital  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Qvortrup","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-7187","authenticated-orcid":false,"given":"Per","family":"Damkier","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Odense University Hospital  Odense Denmark"},{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"EMA.5\u2010Fluorouracil (i.v.) capecitabine and tegafur containing products: Pre\u2010treatment testing to identify DPD\u2010deficient patients at increased risk of severe toxicity|European Medicines Agency [Internet]. [cited 2022 Mar 1]. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/5-fluorouracil-iv-capecitabine-tegafur-containing-products-pre-treatment-testing-identify-dpd#documents-sectio"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107447"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"e_1_2_8_6_1","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"9","author":"Twelves C","year":"2005","journal-title":"N Engl J Med"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00306a033"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021\u20109258(18)34313\u20108"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021\u20109258(17)31638\u20101"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507253130407"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","unstructured":"Hodroj m.fl.2021Issues and limitations of available biomarkers for.pdf.","DOI":"10.1016\/j.esmoop.2021.100125"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100125"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431\u2010019\u20100540\u20100"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30686\u20107"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.09.006"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.94"},{"key":"e_1_2_8_18_1","unstructured":"PubMed.Development and validation of a rapid and sensitive UPLC\u2010MS\/MS method for determination of uracil and dihydrouracil in human plasma. [cited 2022 Mar 3]. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/27179185\/"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010021\u201004354\u20107"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2608"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29025"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20102817"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.138"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5392"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.013"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000245771.82720.c7"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1559325820951367"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175998"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102020\u20100154"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30014"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12981"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/2212697X04666170817123425"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.02.008"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S337147"},{"key":"e_1_2_8_36_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9.Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5\u2010fluorouracil or capecitabine) \u2010 INAHTA Brief [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cited 2022 Aug 2]. Available from:https:\/\/www.has-sante.fr\/jcms\/c_2891090\/en\/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","unstructured":"HamzicS AebiS JoergerM et al.Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.2020Swiss Med Wkly [Internet] Nov 24 [cited 2022 May 12]. Available from:https:\/\/doi.emh.ch\/smw.2020.20375","DOI":"10.4414\/smw.2020.20375"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2020.1870855"},{"key":"e_1_2_8_40_1","unstructured":"NHS England.Clinical Commissioning Urgent Policy Statement: pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies [Internet]. [cited 2022 Aug 2]. Available from:https:\/\/www.england.nhs.uk\/publication\/clinical-commissioning-urgent-policy-statement-pharmacogenomic-testing-for-dpyd-polymorphisms-with-fluoropyrimidine-therapies\/"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:51:19Z","timestamp":1692651079000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/bcpt.13782"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13782","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"type":"print","value":"1742-7835"},{"type":"electronic","value":"1742-7843"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}